Expert Insights

How does assessing risk in PV help you design treatment plans?

Read transcript Close transcript

The optimal timing of therapy really depends on what we mean by therapy. Now that really relates to a patient’s risk of thrombosis. We know that patients who are over the age of sixty, and who have ever had a thrombotic event, are at the highest risk of having a subsequent thrombotic event. For those patients, they usually require a cytoreductive type of therapy, and that can be in the form of hydroxyurea, or interferon, or other modalities. In patients who are lower risk for thrombosis, those are patients less than age sixty or who’ve never had a thrombotic event, those patients usually will require phlebotomy and aspirin as the mainstays of therapy. Regardless of the risk score, all patients will require some form of therapy at the outset when they are diagnosed.

head shot of Dr Shammo
Raajit K Rampal, MD, PhD Hematologic Oncologist Memorial Sloan Kettering Cancer Center | New York, NY
Dr Rampal is a hematology-oncology physician specializing in the treatment of myeloproliferative neoplasms (MPNs) and leukemia. As an active researcher, Dr Rampal is working to understand the genetic events that contribute to the development and progression of MPNs/leukemia and is focused on the development of new and innovative approaches to the treatment of these diseases.